I’m so mad that doctors and companies are taking away remote access. They finally offer accommodations, and then they take them away. First, the pandemic isn’t over. Second, why is it so hard to offer them all time? They are the most helpful accommodations for me.
@amberjans@DrEReinhold My only other surgeon was not careful about sutures and my scars are massive. Dr. Ericson’s are barely visible. They healed really well.
Here is that poster, btw.
https://t.co/oiqU6StgKT
@amberjans@DrEReinhold Dr. William Ericson is the only surgeon I had that knew about hEDS. He is very careful about sutures. In one of his posters, he references “absorbable monofilament sutures and steristrips.” I’m not an MD, so idk exactly what that means, but maybe good to bring up?
@life_is_art___ She also wanted (wants?) to tax mg of opioids (1c per mg) without conversion to mme. So someone on a less potent opioid would pay more ($60/month for 200 mg of tramadol a day, in my case).
Just ridiculous.
Please read through this important thread. I’ll be coming out with more info to add about #Klobuchar and her ties to Rummler and PROP, as well as evidence she took actions she admitted would result in rx opioid and OUD pts being forced to use illicit drugs.
Most cases I’ve read where a pain patient has sued for their right to access opioids have been based on the same principles.
I’m afraid for us all if Roe gets overturned.
I’m afraid we will have much more limited legal recourse. 2/2
The precedent set in Roe v Wade is not just about abortion rights.
It is about medical freedom.
Overturning it will have a chilling affect medical freedom in general. 1/2
🥦🍗🍎 “I just have to squish it with my tongue and it just melts away into your throat.”
Having trouble chewing? Japan's $410 @DeliSofter machine is allowing people to enjoy home-cooked meals even in their later years. @rumireports from Kyoto https://t.co/Ln0aS6q5uE
There were a record 100,000 overdose deaths last year. But the culprits are not the Sacklers or big pharma: opioid prescribing declined by 60 percent since its 2011 peak. The problem is a toxic drug supply one user told @ZachWritesStuff is "pure hell." 1/2 https://t.co/0073Qx1HeL
Most medically trained long-haulers I interviewed were shocked at how quick their own peers were to disregard their medical expertise and tell them their symptoms were in their heads. Their status as patients completely subsumed their qualifications. 2/
https://t.co/57vRpfYG0e
2) so now this 67 yr old man, who takes a schedule 3 controlled substance, is not only abandoned by pain dr due to DEA, but now is medically abandoned by his PCP. Why? All on the name of the “opioid crisis.” Great job @CDCInjury and @supportprop You should be proud.
Interesting. Doc called me & said she’s discharging me cuz they can’t manage my pain. Yet I’m here for my heart.
We’re not redoing any tests since you got them done in May. The daughter and I got phone calls from both docs at the same time.
@thesundaytimes Given we are moving towards using AI more often in healthcare, I really hope they will also look into bias in AI (and how to prevent it/what standards they should be held to).
Bias in AI has the potential for great harm.
@SarahSaysHi2U @Hermes_3XGr8 It definitely works for some people! It helped my mom with cancer pain. But everyone is so different, which is why individualized care is *so* important. lol imagine if we tried to put everyone with depression on the same antidepressant. That would b absurd. Same with pain meds.
The paper found, “53% of successfully tapered [from opioids] patients and 42% of those transitioned onto buprenorphine reported elevated pain.”
And this is not *incredibly concerning* to the authors?
https://t.co/t0Pz9fFu3r
@StefanKertesz@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@supportprop In case anyone sees this, but not my other tweets, here is a piece of data I want. It may not tell us anything about the patients as individuals. The # of patients with increased pain is likely the better metric. But it still bothers me that this is missing.
@adfoxMD @ChadDKollas@PainMedJournal@supportprop 100%
Also statements like this in the discussion:
“There was not a significant difference in median pain intensity from baseline to follow-up among patients successfully transitioned to buprenorphine”
But where is the median follow-up value?
@StefanKertesz@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@supportprop 1/Thank you for the work you do. I has a similar take-away. Other than some missing data (maybe changes nothing, but it’s weird to exclude), my main source of frustration was not the data itself, but rather that it seems acceptable to them that over half the patients are subject